同和药业(300636.SZ)：富马酸伏诺拉生原料药通过CDE审批

Group 1 - The core point of the article is that Tonghua Dongbao Pharmaceutical (300636.SZ) has received approval from the National Medical Products Administration (NMPA) for its active pharmaceutical ingredient, Fumaric Acid Vorinostat, which is primarily used for the treatment of gastroesophageal reflux disease [1] Group 2 - The approval was obtained through the CDE's "Raw and Auxiliary Material Registration Information Publicity" platform [1] - Fumaric Acid Vorinostat is specifically indicated for the treatment of reflux esophagitis [1]